Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 5, 2011, Pages 1975-1981

  Gregory, Matthew A ^a   Bobardt, Michael ^b   Obeid, Susan ^c   Chatterji, Udayan ^b   Coates, Nigel J ^a   Foster, Teresa ^a   Gallay, Philippe ^b   Leyssen, Pieter ^c   Moss, Steven J ^a   Neyts, Johan ^c   Nur e Alam, Mohammad ^a   Paeshuyse, Jan ^c   Piraee, Mahmood ^a   Suthar, Dipen ^a   Warneck, Tony ^a   Zhang, Ming Qiang ^a   Wilkinson, Barrie ^a  

^a BIOTICA TECHNOLOGY LTD   (United Kingdom)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHILIN INHIBITOR; CYCLOSPORIN A; ISOMERASE; SANGLIFEHRIN A; SANGLIFEHRIN B; SANGLIFEHRIN C; SANGLIFEHRIN D; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STRUCTURE; ENZYME ACTIVITY; HEPATITIS C VIRUS; MALE; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL;

ANIMALS; ANTIVIRAL AGENTS; BLOTTING, WESTERN; CELL LINE; CYCLOPHILINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEP G2 CELLS; HEPACIVIRUS; HUMANS; LACTONES; MALE; MICE; MOLECULAR STRUCTURE; VIRUS REPLICATION;

EID: 79955536124     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01627-10     Document Type: Article

References (52)

1. Braaten, D., and J. Luban. 2001. Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells. EMBO J. 20:1300-1309. (Pubitemid 32233970)
2. Chatterji, U., et al. 2009. The isomerase active site of cyclophilin A is critical for hepatitis C virus replication. J. Biol. Chem. 284:16998-17005.
3. Chatterji, U., et al. 2005. Naturally occurring capsid substitutions render HIV-1 cyclophilin A independent in human cells and TRIM-cyclophilin- resistant in owl monkey cells. J. Biol. Chem. 280:40293-40300.
4. Chatterji, U., et al. 2010. HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors. J. Hepatol. 53:50-56.
5. Ciesek, S., et al. 2009. Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. Hepatology 50:1638-1645.
6. Coelmont, L., et al. 2009. Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob. Agents Chemother. 53:967-976.
7. Colgan, J., M. Asmal, and J. Luban. 2000. Isolation, characterization and targeted disruption of mouse Ppia: cyclophilin A is not essential for mammalian cell viability. Genomics 68:167-178.
8. Crabbé, R., et al. 2009. An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C. Expert Opin. Investig. Drugs 18:211-220.
9. Delang, L., L. Coelmont, and J. Neyts. 2010. Antiviral therapy for hepatitis C virus: beyond the standard of care. Viruses (Basel) 2:826-866.
10. Reference deleted.
11. Reference deleted.
12. Dolinski, K., S. Muir, M. Cardenas, and J. Heitman. 1997. All cyclophilins and FK506 binding proteins are, individually and collectively, dispensable for viability in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. U. S. A. 94:13093-13098.
13. Fehr, T., J. Kallen, L. Oberer, J. J. Sanglier, and W. Schilling. 1999. Sanglifehrins A, B, C and D, novel cyclophilin-binding compounds isolated from Streptomyces sp. A92-308110. II. Structure elucidation, stereochemistry and physico-chemical properties. J. Antibiot. (Tokyo) 52:474-479.
14. Fernandes, F., I. U. Ansari, and R. Striker. 2010. Cyclosporine inhibits a direct interaction between cyclophilins and hepatitis C NS5A. PLoS One 5:e9815.
15. Flisiak, R., et al. 2009. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology 49:1460-1468.
16. Flisiak, R., et al. 2008. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 47:817-826. (Pubitemid 351449673)
17. Gaither, L. A., et al. 2010. Multiple cyclophilins involved in different cellular pathways mediate HCV replication. Virology 397:43-55.
18. Goto, K., K. Watashi, D. Inoue, M. Hijikata, and K. Shimotohno. 2009. Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor. Cancer Sci. 100:1943-1950.
19. Hanoulle, X., et al. 2009. Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyl cis/trans isomerase activity of cyclophilins A and B. J. Biol. Chem. 284:13589-13601.
20. Herrler, M., H. Bang, and M. A. Marahiel. 1994. Cloning and characterization of ppiB, a Bacillus subtilis gene which encodes a cyclosporin A-sensitive peptidyl-prolyl cis-trans isomerase. Mol. Microbiol. 11:1073-1083.
21. Hopkins, S., et al. 2010. SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Antimicrob. Agents Chemother. 54:660-672.
22. Huang, L., et al. 2004. Purification and characterization of hepatitis C virus non-structural protein 5A expressed in Escherichia coli. Protein Expr. Purif. 37:144-153.
23. Inoue, K., et al. 2007. Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. Hepatology 45:921-928. (Pubitemid 46631561)
24. Ishii, N., et al. 2006. Diverse effects of cyclosporine on hepatitis C virus strain replication. J. Virol. 80:4510-4520.
25. Jacobson, I. M., et al. 2007. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology 46:982-990. (Pubitemid 350144762)
26. Kallen, J., R. Sedrani, G. Zenke, and J. Wagner. 2005. Structure of human cyclophilin A in complex with the novel immunosuppressant sanglifehrin A at 1.6 A resolution. J. Biol. Chem. 280:21965-21971.
27. Kapturczak, M. H., H. U. Meier-Kriesche, and B. Kaplan. 2004. Pharmacology of calcineurin antagonists. Transplant Proc. 36:25S-32S.
28. Kronenberger, B., and S. Zeuzem. 2009. Current and future treatment options for HCV. Ann. Hepatol. 8:103-112.
29. Manns, M. P., et al. 2007. The way forward in HCV treatment - finding the right path. Nat. Rev. Drug Discov. 6:991-1000.
30. Mathy, J. E., S. Ma, T. Compton, and K. Lin. 2008. Combinations of cyclophilin inhibitor NIM811 with hepatitis C virus NS3-4A protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance. Antimicrob. Agents Chemother. 52:3267-3275.
31. Melnikova, I. 2008. Hepatitis C therapies. Nat. Rev. Drug Discov. 7:799-800.
32. Nelson, D. R., et al. 2009. Efficacy and safety of the cyclophilin inhibitor DEBIO-025 in combination with pegylated interferon alpha-2A and ribavirin in previously null-responder genotype 1 HCV patients. J. Hepatol. 50:S40.
33. Paeshuyse, J., et al. 2006. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 43:761-770.
34. Paeshuyse, J., et al. 2008. Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors. Antimicrob. Agents Chemother. 52:3433-3437.
35. Parfieniuk, A., J. Jaroszewicz, and R. Flisiak. 2007. Specifically targeted antiviral therapy for hepatitis C virus. World J. Gastroenterol. 13:5673-5681.
36. Pawlotsky, J. M. 2005. Current and future concepts in hepatitis C therapy. Semin. Liver Dis. 25:72-83.
37. Pawlotsky, J. M., S. Chevaliez, and J. G. McHutchison. 2007. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 132:1979-1998.
38. Pockros, P. 2008. Emerging therapies for chronic hepatitis C virus. Gastroenterol. Hepatol. 4:729-734.
39. Poynard, T., M. F. Yuen, V. Ratziu, and C. L. Lai. 2003. Viral hepatitis C. Lancet 362:2095-2100.
40. Puyang, X., et al. 2010. Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors. Antimicrob. Agents Chemother. 54:1981-1987.
41. Ritschel, W. A., N. N. Vachharajani, R. D. Johnson, and A. S. Hussain. 1992. The allometric approach for interspecies scaling of pharmacokinetic parameters. Comp. Biochem. Physiol. C 103:249-253.
42. Robida, J. M., H. B. Nelson, Z. Liu, and H. Tang. 2007. Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro. J. Virol. 81:5829-5840. (Pubitemid 46847020)
43. Sanglier, J. J., et al. 1999. Sanglifehrins A, B, C and D, novel cyclophilin-binding compounds isolated from Streptomyces sp. A92-308110. I. Taxonomy, fermentation, isolation and biological activity. J. Antibiot. (Tokyo) 52:466-473.
44. Sedrani, R., et al. 2003. Sanglifehrin-cyclophilin interaction: degradation work, synthetic macrocyclic analogues, X-ray crystal structure, and binding data. J. Am. Chem. Soc. 125:3849-3859.
45. Tropschug, M., I. B. Barthelmess, and W. Neupert. 1989. Sensitivity to cyclosporin A is mediated by cyclophilin in Neurospora crassa and Saccharomyces cerevisiae. Nature 342:953-955. (Pubitemid 20021349)
46. Vrolijk, J. M., et al. 2003. A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. J. Virol. Methods 110:201-209. (Pubitemid 36645265)
47. Wainberg, M. A., and J. L. Martinez-Cajas. 2009. Sequencing of therapy to avoid resistance and the need for new antiretroviral drugs in the treatment of HIV disease. Infect. Disord. Drug Targets 9:172-190.
48. Wang, P., and J. Heitman. 2005. The cyclophilins. Genome Biol. 6:226.
49. Watashi, K. 2010. Alisporivir, a cyclosporin derivative that selectively inhibits cyclophilin, for the treatment of HCV infection. Curr. Opin. Investig. Drugs 11:213-224.
50. Watashi, K., et al. 2005. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol. Cell 19:111-122. (Pubitemid 40884662)
51. Yang, F., et al. 2008. Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. J. Virol. 82:5269-5278. (Pubitemid 351705235)
52. Zenke, G., et al. 2001. Sanglifehrin A, a novel cyclophilin-binding compound showing immunosuppressive activity with a new mechanism of action. J. Immunol. 166:7165-7171. (Pubitemid 32525588)